These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27881506)

  • 1. Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective.
    Packer M
    Circulation; 2016 Nov; 134(21):1664-1678. PubMed ID: 27881506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A global ranking approach to end points in trials of mechanical circulatory support devices.
    Felker GM; Anstrom KJ; Rogers JG
    J Card Fail; 2008 Jun; 14(5):368-72. PubMed ID: 18514927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
    Anker SD; Schroeder S; Atar D; Bax JJ; Ceconi C; Cowie MR; Crisp A; Dominjon F; Ford I; Ghofrani HA; Gropper S; Hindricks G; Hlatky MA; Holcomb R; Honarpour N; Jukema JW; Kim AM; Kunz M; Lefkowitz M; Le Floch C; Landmesser U; McDonagh TA; McMurray JJ; Merkely B; Packer M; Prasad K; Revkin J; Rosano GM; Somaratne R; Stough WG; Voors AA; Ruschitzka F
    Eur J Heart Fail; 2016 May; 18(5):482-9. PubMed ID: 27071916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key issues in end point selection for heart failure trials: composite end points.
    Neaton JD; Gray G; Zuckerman BD; Konstam MA
    J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure.
    Packer M; Holcomb R; Abraham WT; Anker S; Dickstein K; Filippatos G; Krum H; Maggioni AP; McMurray JJV; Mebazaa A; O'Connor C; Peacock F; Ponikowski P; Ruschitzka F; van Veldhuisen DJ; Holzmeister J;
    Eur J Heart Fail; 2017 May; 19(5):673-681. PubMed ID: 27862700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure.
    Packer M
    J Card Fail; 2001 Jun; 7(2):176-82. PubMed ID: 11420770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End points in heart failure-are we doing it right?
    Goenka L; George M; Selvarajan S
    Eur J Clin Pharmacol; 2017 Jun; 73(6):651-659. PubMed ID: 28280889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials.
    Packer M; McMurray JJV; Krum H; Kiowski W; Massie BM; Caspi A; Pratt CM; Petrie MC; DeMets D; Kobrin I; Roux S; Swedberg K;
    JACC Heart Fail; 2017 May; 5(5):317-326. PubMed ID: 28449795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letter by Brown and Ezekowitz Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective".
    Brown PM; Ezekowitz JA
    Circulation; 2017 Apr; 135(15):e889-e891. PubMed ID: 28396384
    [No Abstract]   [Full Text] [Related]  

  • 11. Response by Packer to Letter Regarding Article, "Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure: A 20-Year Perspective".
    Packer M
    Circulation; 2017 Apr; 135(15):e892-e893. PubMed ID: 28396385
    [No Abstract]   [Full Text] [Related]  

  • 12. Multitype Events and the Analysis of Heart Failure Readmissions: Illustration of a New Modeling Approach and Comparison With Familiar Composite End Points.
    Brown PM; Ezekowitz JA
    Circ Cardiovasc Qual Outcomes; 2017 Jun; 10(6):. PubMed ID: 28630372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial.
    Liu C; Hou Y; Wang X; Zhao Z; Liu Z; Zhai J; Mao J; Shang H
    Trials; 2015 May; 16():222. PubMed ID: 25994188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial.
    Kalter-Leibovici O; Freimark D; Freedman LS; Kaufman G; Ziv A; Murad H; Benderly M; Silverman BG; Friedman N; Cukierman-Yaffe T; Asher E; Grupper A; Goldman D; Amitai M; Matetzky S; Shani M; Silber H;
    BMC Med; 2017 May; 15(1):90. PubMed ID: 28457231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?
    Brown PM; Ezekowitz JA
    Circ Heart Fail; 2017 Jan; 10(1):. PubMed ID: 28077429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of surrogate end points in the evaluation of drugs for heart failure.
    Lipicky RJ; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):179A-184A. PubMed ID: 8376690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite outcome measures in a pragmatic clinical trial of chronic heart failure management: A comparative assessment.
    Chang S; Davidson PM; Newton PJ; Macdonald P; Carrington MJ; Marwick TH; Horowitz JD; Krum H; Reid CM; Chan YK; Scuffham PA; Sibbritt D; Stewart S;
    Int J Cardiol; 2015 Apr; 185():62-8. PubMed ID: 25791092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.
    Fisher SA; Brunskill SJ; Doree C; Mathur A; Taggart DP; Martin-Rendon E
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007888. PubMed ID: 24777540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.